Replies to post #260980 on Avid Bioservices Inc (CDMO)

[Carboat]

In PII the MOS of the CTRL arm was 5.6 but sicker patients. In PIII the studies with healthier patients give an historical approx. 10 months.

The PII was DOSE SWITCHED in the disadvantage of Bavituximab

The PII was a small flawed study. Using that as a benchmark for anything is equally flawed as confirmed by the PIII. The simplest explenation is usually right. In this case Sunrise failed, PPHM expressed disappointment in its failure and postponed (cancelled you really don't think they will restart do you?) all bavi/chemo trials. It could not be much simpler than that. Bavi and chemo are not effective. First line, pancreatic, Sunrise - how much more evidence could anyone need?

[jbainseky]

B) I did NOT expect Bavi to outperform PII results in SUNRISE PIII. Not sure how you came to that conclusions

CTRL: 5.6 vs 10 mounts (RECENT studies PPHM speaks about).
BAVI: 12 vs either 10+2=12 (no margin), 12+2=14 (my GUESS margin of 10+2 for CTRL arm)

WOW, I didn't realize the Phase 2 MOS was that high!! And here I thought all along the phase 2 MOS was less than 12 months, what was I thinking?

FFTT

JBAIN